These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 7934446)

  • 1. The role of tyrosinase in autoimmune vitiligo.
    Song YH; Connor E; Li Y; Zorovich B; Balducci P; Maclaren N
    Lancet; 1994 Oct; 344(8929):1049-52. PubMed ID: 7934446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tyrosinase as an autoantigen in patients with vitiligo.
    Baharav E; Merimski O; Shoenfeld Y; Zigelman R; Gilbrud B; Yecheskel G; Youinou P; Fishman P
    Clin Exp Immunol; 1996 Jul; 105(1):84-8. PubMed ID: 8697641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunoprecipitation of melanogenic enzyme autoantigens with vitiligo sera: evidence for cross-reactive autoantibodies to tyrosinase and tyrosinase-related protein-2 (TRP-2).
    Kemp EH; Gawkrodger DJ; Watson PF; Weetman AP
    Clin Exp Immunol; 1997 Sep; 109(3):495-500. PubMed ID: 9328128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoantibodies to tyrosinase: the bridge between melanoma and vitiligo.
    Fishman P; Merimski O; Baharav E; Shoenfeld Y
    Cancer; 1997 Apr; 79(8):1461-4. PubMed ID: 9118024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reactivity to tyrosinase: expression in cancer (melanoma) and autoimmunity (vitiligo).
    Merimsky O; Shoenfeld Y; Baharav E; Zigelman R; Fishman P
    Hum Antibodies Hybridomas; 1996; 7(4):151-6. PubMed ID: 9140726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of tyrosinase autoantibodies in patients with vitiligo using 35S-labeled recombinant human tyrosinase in a radioimmunoassay.
    Kemp EH; Gawkrodger DJ; MacNeil S; Watson PF; Weetman AP
    J Invest Dermatol; 1997 Jul; 109(1):69-73. PubMed ID: 9204957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunity to melanin and to tyrosinase in melanoma patients, and in people with vitiligo.
    Dorđić M; Matić IZ; Filipović-Lješković I; Džodić R; Sašić M; Erić-Nikolić A; Vuletić A; Kolundžija B; Damjanović A; Grozdanić N; Nikolić S; Pralica J; Dobrosavljević D; Rašković S; Andrejević S; Juranić Z
    BMC Complement Altern Med; 2012 Jul; 12():109. PubMed ID: 22834951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteomic scan for tyrosinase peptide antigenic pattern in vitiligo and melanoma: role of sequence similarity and HLA-DR1 affinity.
    Lucchese A; Willers J; Mittelman A; Kanduc D; Dummer R
    J Immunol; 2005 Nov; 175(10):7009-20. PubMed ID: 16272362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of experimental autoimmune vitiligo by oral administration of mushroom tyrosinase.
    Zehtab T; Yazdanparast R; Rafieii S
    Cytobios; 2001; 105(408):27-34. PubMed ID: 11368265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autoantibodies to tyrosinase-related protein-1 detected in the sera of vitiligo patients using a quantitative radiobinding assay.
    Kemp EH; Waterman EA; Gawkrodger DJ; Watson PF; Weetman AP
    Br J Dermatol; 1998 Nov; 139(5):798-805. PubMed ID: 9892944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxidized tyrosinase: A possible antigenic stimulus for non-segmental vitiligo autoantibodies.
    Al-Shobaili HA; Rasheed Z
    J Dermatol Sci; 2015 Sep; 79(3):203-13. PubMed ID: 26137927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoantibodies to human melanocyte-specific protein pmel17 in the sera of vitiligo patients: a sensitive and quantitative radioimmunoassay (RIA).
    Kemp EH; Gawkrodger DJ; Watson PF; Weetman AP
    Clin Exp Immunol; 1998 Dec; 114(3):333-8. PubMed ID: 9844040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytotoxic T lymphocyte reactivity to gp100, MelanA/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients.
    Mandelcorn-Monson RL; Shear NH; Yau E; Sambhara S; Barber BH; Spaner D; DeBenedette MA
    J Invest Dermatol; 2003 Sep; 121(3):550-6. PubMed ID: 12925214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Why tyrosinase for treatment of melanoma.
    Song YH
    Lancet; 1997 Jul; 350(9071):82-3. PubMed ID: 9228956
    [No Abstract]   [Full Text] [Related]  

  • 15. Vitiligo antibodies are not directed to tyrosinase.
    Xie Z; Chen D; Jiao D; Bystryn JC
    Arch Dermatol; 1999 Apr; 135(4):417-22. PubMed ID: 10206048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of epitopes on tyrosinase which are recognized by autoantibodies from patients with vitiligo.
    Kemp EH; Waterman EA; Gawkrodger DJ; Watson PF; Weetman AP
    J Invest Dermatol; 1999 Aug; 113(2):267-71. PubMed ID: 10469315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoimmune response against tyrosinase induces depigmentation in C57BL/6 black mice.
    Al Robaee AA; Alzolibani AA; Rasheed Z
    Autoimmunity; 2020 Dec; 53(8):459-466. PubMed ID: 33084421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Expression and purification of epitope peptide of human tyrosinase and its antigenicity in vitiligo patients].
    Guan CP; Zhou MN; Li YW; Wei XD; Xu AE
    Zhonghua Yi Xue Za Zhi; 2007 Sep; 87(34):2408-11. PubMed ID: 18036319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The melanin-concentrating hormone receptor 1, a novel target of autoantibody responses in vitiligo.
    Kemp EH; Waterman EA; Hawes BE; O'Neill K; Gottumukkala RV; Gawkrodger DJ; Weetman AP; Watson PF
    J Clin Invest; 2002 Apr; 109(7):923-30. PubMed ID: 11927619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Melanoma-associated hypopigmentation: where are the antibodies?
    Merimsky O; Shoenfeld Y; Baharav E; Altomonte M; Chaitchik S; Maio M; Ferrone S; Fishman P
    Am J Clin Oncol; 1996 Dec; 19(6):613-8. PubMed ID: 8931683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.